VYCOR MEDICAL, INC.: 10-Q filed 2023-11-13
What VYCOR MEDICAL, INC. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 43 published measures, 120 facts as tagged in accession 0001493152-23-040566.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-13
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-040566 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VYCOR MEDICAL, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,054,469 | USD | |
| At 2022-12-31 | 860,178 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 4,286,890 | USD | |
| At 2022-12-31 | 3,801,049 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -3,232,421 | USD | |
| At 2023-06-30 | -3,018,332 | USD | |
| At 2022-12-31 | -2,940,871 | USD | |
| At 2022-09-30 | -2,819,502 | USD | |
| At 2022-06-30 | -2,599,297 | USD | |
| At 2021-12-31 | 2,395,213 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 69,055 | USD | |
| At 2022-12-31 | 37,035 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -51,904 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 23,364 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -114,807 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -288,369 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 23,922 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -183,662 | USD | 273 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 308,593 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,152,355 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 309,969 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 951,725 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 11,578 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 128,392 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -3,482 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -3,102 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -32,727,435 | USD | |
| At 2022-12-31 | -32,426,429 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 32,628,835 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 32,595,320 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 31,997,281 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 31,432,040 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 32,628,835 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 32,595,320 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 31,997,281 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 31,432,040 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.01 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.01 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.01 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.02 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.01 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.01 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.01 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.02 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 261,602 | USD | |
| At 2022-12-31 | 303,770 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 7,777 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 187,381 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -25,481 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 104,247 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -88,045 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -215,318 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 625,888 | USD | |
| At 2022-12-31 | 517,763 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-29 to 2016-10-31 | 12,000 | EUR | 3 |
| 2012-06-29 to 2012-06-30 | 12,000 | EUR | 2 |
| 2016-10-29 to 2016-10-31 | 13,200 | USD | 3 |
| 2012-06-29 to 2012-06-30 | 13,200 | USD | 2 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 4,031,212 | USD | |
| At 2022-12-31 | 3,654,796 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 113,729 | USD | |
| At 2022-12-31 | 200,044 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 255,266 | USD | |
| At 2022-12-31 | 156,204 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 301,740 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 945,178 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 355,815 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,063,550 | USD | 273 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 204,739 | USD | |
| At 2022-12-31 | 248,874 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 276,259 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,049,425 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 267,770 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 848,232 | USD | 273 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 280,113 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 881,744 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 341,256 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,019,693 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 7,250 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 20,308 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 32,628,835 | shares | |
| At 2022-12-31 | 32,527,172 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 29,365,070 | USD | |
| At 2022-12-31 | 29,355,626 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 127,677 | USD | |
| At 2022-12-31 | 127,675 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 160,979 | USD | |
| At 2022-12-31 | 32,645 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 156,681 | USD | |
| At 2022-12-31 | 29,591 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 95,932 | USD | |
| At 2022-12-31 | 74,438 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -51,479 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 26,881 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -112,312 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -283,835 | USD | 273 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -51,904 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 23,366 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -114,806 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -288,368 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -214,089 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -301,006 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -276,992 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -612,739 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 45,650 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 46,073 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -25,998 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -77,366 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -24,267 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -68,517 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 4,176 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 6,579 | USD | 273 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 0 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 0 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 99,062 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 54,462 | USD | 273 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -44,135 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 71,381 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -86,315 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -8,713 | USD | 273 |
Inspect the source
- Entity
- VYCOR MEDICAL, INC. / CIK 0001424768
- Captured
- 2026-09-20T08:03:40.055Z
- SEC response SHA-256
5a14e6ff2e4ebac913c15e977f951bb2964df57677e781dac80300af4dfd59db
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001424768.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))